FDA published a perspective article in JAMA that describes the agency’s current regulatory thinking for the development of CAR T-cell therapies.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
